According to the Zhitong Finance App, Quanxin Bio-B (02509.HK) announced that on November 5, 2026, the company and Caldera Therapeutics, Inc. entered into an external licensing agreement for a pre-clinical bispecific antibody project targeting TL1a and IL-17 (specifically IL-17A and IL-17A/F).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.